Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- MSD Files Allergy Drug Desloratadine in Japan
October 16, 2015
- Eisai’s GI Disease Biz to Integrate with Ajinomoto Pharma
October 15, 2015
- Plavix Retains Top Slot in FY2014 Japan Drug Sales Ranking: Jiho Tally
October 14, 2015
- Toyama Chemical Licenses RA Drug to Turkish Firm
October 14, 2015
- Astellas Gains Worldwide Rights to Next-Gen DNA Vaccines
October 13, 2015
- (PRESS RELEASE) Shionogi to Spin Off Consumer Healthcare Biz Next Year
October 13, 2015
- Eisai’s Thyroid Cancer Drug Lenvima Approved in S. Korea
October 13, 2015
- AZ Begins Japan PI Trial of CTLA-4 Inhibitor for Malignant Mesothelioma
October 9, 2015
- Ethical Drug Sales Surge 9.0% in August: Crecon Report
October 8, 2015
- Meiji Seika Pharma Commences Long-Term Studies of Safinamide
October 8, 2015
- Merck Lauds Nobel Medicine Prize Winners Omura, Campbell
October 7, 2015
- GreenPeptide Files IND in US for Cancer Peptide Vaccine
October 7, 2015
- Anti-Obesity Effect of Rare Sugar D-Psicose Confirmed: Matsutani Chemical Industry
October 7, 2015
- Eisai Offers Indonesia 151 Million Tablets of Elephantiasis Drug for Free
October 6, 2015
- GSK to Seek COPD Indication for Relvar in January-March 2016
October 6, 2015
- Belsomra Most Heavily Pitched Drug in July: Anterio Ranking
October 5, 2015
- Japan OTC Drug Market Logs 1st Rise in 5 Years: Fuji Keizai
October 5, 2015
- Mitsubishi Tanabe Wins Rights to Regeneron’s NGF Antibody in Asia
October 5, 2015
- Otsuka Files Combination Glaucoma Eye Drops in Japan
October 2, 2015
- ASKA Takes Over 2 Anti-Thyroid Drugs from Chugai
October 2, 2015
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…